The effects of Fhit on tumorigenesis after multi-exposure to low-dose radiation

International Journal of Clinical and Experimental Medicine

Volumn 2, Issue 4, 2009, Pages 348-353

  Yu, Xiaoyan ^a,b   Lu, Lin ^c   Wen, Siyuan ^a,d   Wang, Ya ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Fhit; Ionizing radiation; Low dose; Tumorigenesis

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; INTESTINE TUMOR; IONIZING RADIATION; KIDNEY TUMOR; LIVER CARCINOGENESIS; LUNG CARCINOGENESIS; MALE; MOUSE; NONHUMAN; OVARY TUMOR; PAROTID GLAND TUMOR; PROTEIN FUNCTION; RADIATION DOSE; RADIATION EXPOSURE; TESTIS TUMOR; TRANSGENIC MOUSE; WILD TYPE;

MUS;

EID: 74549201520     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Olivieri G, Bodycote J and Wolff S. Adaptive response of human lymphocytes to low concentrations of radioactive thymidine. Science 1984; 223: 594-597.
2. Sanderson BJ and Morley AA. Exposure of human lymphocytes to ionizing radiation reduces mutagenesis by subsequent ionizing radiation. Mut. Res. 1986; 164: 347-351.
3. Laval F. Pretreatment with oxygen species increases the resistance of mammalian cells to hydrogen peroxide and g-rays. Mut. Res. 1988; 201: 73-79.
4. Schäppi-Büchi C. On the genetic background of the adaptive response to X-rays in Drosophila melanogaster. Int. J Radiat. Biol. 1994; 65: 427-435.
5. Zhou PK, Xiang XQ, Sun WZ, Liu XY, Zhang YP and Wei K. Adaptive response to mutagenesis and its molecular basis in a human T-cell leukemia line primed with a low dose of gamma-rays. Radiat Environ Biophys. 1994; 33: 211-217.
6. Sasaki MS. On the reaction kinetics of the radioadaptive response in cultured mouse cells. Int. J Radiat. Biol. 1995; 68: 281-291.
7. Rigaud O, Laquerbe A and Moustacchi E. DNA sequence analysis of HPRT- mutants induced in human lymphoblastoid cells adapted to ionizing radiation. Radiat. Res. 1995; 144: 181-189.
8. Ueno AM, Vannais DB, Gustafson DL, Wong JC and Waldren CA. A low, adaptive dose of gamma-rays reduced the number and altered the spectrum of S1- mutants in human-hamster hybrid AL cells. Mut. Res. 1996; 358: 161-169.
9. Azzam EI, Toledo SMD, Raaphorst GP and Mitchel REJ. Low-dose ionizing radiation decreases the frequency of neoplastic transformation to a level below the spontaneous rate in C3H 10T1/2 Cells Radiat. Res. 1996; 146: 369-373.
10. Broome EJ, Brown DL and Mitchel REJ. Dose responses for adaption to low doses of (60)Co gamma rays and (3)H beta particles in normal human fibroblasts Radiat. Res. 2002; 158: 181-186.
11. Mitchel REJ, Jackson JS, McCann RA and Boreham DR. The adaptive response modifies Latency for radiation-induced myeloid leukemia in CBA/H Mice Radiat. Res. 1999; 152: 273-279.
12. Sakai K, Iwasaki T, Hoshi Y, Ina Y, Fujita K, Nomura T, Tanooka H, Bing W and Hayata I. Adaptive responses to low dose or low doserate irradiation in mice., in, Fifty-third Annual Meeting of the Radiation Research Society, Philadelphia, PA, USA, 2006, pp. 18.
13. Huebner K and Croce CM. Cancer and the FRA3B//FHIT fragile locus: it's a HIT. Br J Cancer 2003; 88: 1501-1506.
14. Fong LYY, Fidanza V, Zanesi N, Lock, LF, Siracusa LD, Mancini R, Siprashvili Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM and Huebner K. Muir-torre-like syndrome in Fhitdeficient mice. Proc Nati Acad Sci, USA 2000; 97: 4742-4747.
15. Ottey M, Han S-Y, Druck T, Barnoski B, Croce CM, Fairchild C, Wang Y and Huebner K. Fhit deficient normal and cancer cells are mitomycin C and UVC resistant. Brit. J. Cancer 2004; 91: 1669-1677.
16. Lu L, Hu B, Yu F and Wang Y. Low dose radiation-induced adaptive response preventing HPRT mutation is Fhit independent Int. J. Radiat. Biol. 2009; 85: 532-537.
17. Jeggo PA. DNA Breakage and Repair. Advances Gen. 1998; 38: 186-218.
18. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis. 2002; 23: 687-696.
19. Ma Y, Pannicke U, Schwarz K and Lieber MR. Hairpin Opening and overhang processing by an artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002; 108: 781-794.
20. Abbas A, Lichtman A and Pillai S. Cellular and Molecular Immunology. 7th Edition, Publisher: W.B. Saunders Co. 2010.
21. Liu S-Z. Cancer control related to stimulation of immunity by low-dose radiation. Dose Response. 2007; 5: 39-47.
22. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM and Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancer. Cell 1996; 84: 587-597.
23. Huebner K and Croce CM. FRA3B and other common fragile sites: the weakest links. Nature Reviews Cancer 2001; 1: 214-221.
24. Zanesi N, Pekarsky Y and Croce CM. A mouse model of the fragile gene FHIT: From carcino-genesis to gene therapy and cancer prevention. Mut. Res. 2005; 591: 103-109.
25. Deng Y, Zhou D and Lu Y. Frequent allelic loss at the FRA3B site in endemic nasopharyngeal carcinoma: association with clinical features and Epstein-Barr virus infection. J Larynogl Otol 2007; 121: 1073-1078.
26. Siraj A, Ibrahim M, Al-Rasheed M, Bu R, Bavi P, Jehan Z, Abubaker J, Murad W, Al-Dayel F, Ezzat A, El-Solh H, Uddin S and Al-Kuraya K. Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East. Ann Hematol 2007; 86: 887-895.
27. Baker A, Cecener G, Tunca B, Guler G, Egeli U and Tolunay, S. Investigation of mutations and expression of the FHIT gene in Turkish patients with brain metastases derived from non-small cell lung cancer. Tomori 2007; 93: 604-607.
28. Levin A, Ray A, Zuhlke K, Douglas J and Cooney K. Association between germline variation in the FHIT gene and prostate cancer in Caucasians and African Americans. Cancer Epidemiol Boimarkers Prev 2007; 16: 1294-1297.
29. Fisher D and McLennan A. Correlation of intra-cellular diadenosine triphosphate (Ap3A) with apoptosis in Fhit-positive HEK293 cells. Cancer Lett 2008; 259: 186-191.
30. Yasugi A, Yashima K, Hara A, Koda M, Kawaguchi K, Harada K, Andachi H and Murawaki Y. Fhit, Mlh1, P53 and phenotypic expression in the early stage of colorectal neoplasms. Oncol Rep 2008; 19: 41-47.
31. Rimessi A, Marchi S, Fotino C, Romagnoli A, Huebner K, Croce CM, Pinton P and Rizzuto R. Intramitochondrial calcium regulation by the FHIT gene product sensitizes to apoptosis. Proc Nati Acad Sci USA 2009; 106: 12753-12758.
32. Hu B, Han S-Y, Wang X, Ottey M, Potoczek MB, Dicker A, Huebner K and Wang Y. Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Phys. 2005; 202: 518-523.
33. Ishii H, Wang Y and Huebner K. A Fhit-ing role in the DNA damage checkpoint response. Cell Cycle 2007; 6: 1044-1048.
34. Semba S and Huebner K. Protein expression profiling identifies cyclophilin A as a molecular target in Fhit-mediated tumor suppression. Mol Cancer Res 2006; 4: 529-538.
35. Semba S, Trapasso F, Fabbri M, McCorkell KA, Volinia S, Druck T, Iliopoulos D, Pekarsky Y, Ishii H, Garrison PN, Barnes LD, Croce CM and Huebner K. Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene 2006; 25: 2860-2872.